


제7기 결산공고
2023년 03월 23일 디어젠 주식회사 대표이사 강 길 수
Read More
제7기 정기주주총회 소집 공고
당사는 이사회 결의로 상법 제363조 및 당사 정관에 의거하여 아래와 같이 정기주주총회를 개최하고자 통지하오니 참석하여 주시기 바랍니다.
Read More
Deargen Announces Patent Application for a TNBC Target Novel Drug Candidate Using AI
Deargen applied patent for a novel target compound candidate.
Read More
Deargen-Samsung Medical Center signed a joint research agreement using ‘AI for The Development of Alzheimer Treatment’
Deargen collaboration with Samsung Seoul Hospital, to discover new Alzheimer’s treatments using AI technology.
Read More
Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models
At ACM CHIL 2021, Deargen presented study results on a model of simultaneously optimizing multiple properties of molecules.
Read More
Deargen, Nominated as TOP10 for bioanalytical service company
Deargen: Laveraging AI to Accelerate New Drug Development.
Read More
Deargen-Uppthera, co-development of Proteolytic drugs
Deargen and Uptera selected two target proteins, including anti-cancer drugs, and signed a joint research contract.
Read More
AI-based Drug Discovery, What would be the limitation?
AI-based Drug Discovery, What would be the limitation?
Read More
Handok- Signed a new drug development contract using artificial intelligence of Deargen
HANDOK and Deargen will conduct joint researches on “oncology” and other diseases using DearDTI.
Read More